Published Studies Related to Humalog Mix75/25 (Insulin Lispro Protamine Suspension / Insulin Lispro Injection)
Well-designed clinical trials related to Humalog Mix75/25 (Insulin Lispro Protamine Suspension / Insulin Lispro Injection)
Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes. [2010.05]
The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes. [2005.12]
Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. [2004.04]
Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus. [2003.09]
Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus. [2003.03]
Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. [2002.01]
Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes. [2000.12]
Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. [2000.02]
Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. [1999.03]
Other research related to Humalog Mix75/25 (Insulin Lispro Protamine Suspension / Insulin Lispro Injection)
Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. [2010.05]
Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus
insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing
to achieve control with starter insulin treatment and continuing oral
antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE
trial. [2010]
Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance. [2008.01]
Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus. [2008]
Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA(1c) and pre- and postprandial blood glucose levels in patients with type 2 diabetes: A multinational, 24-week, randomized, open-label, parallel-group comparison. [2007.11]
Advancing Insulin Therapy in Type 2 Diabetes, Previously Treated with Glargine Plus Oral Agents: Prandial Premixed (Lispro/ILPS) vs. Basal/Bolus (Glargine/Lispro) Therapy. [2007.10.12]
Premixed insulin analogues for the treatment of diabetes mellitus. [2006]
The impact of the timing of Humalog((R)) Mix25trade mark injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes. [2005.11.24]
|
